Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;43(5):799-810.
doi: 10.1038/s41587-024-02307-y. Epub 2024 Jul 2.

Tracking-seq reveals the heterogeneity of off-target effects in CRISPR-Cas9-mediated genome editing

Affiliations

Tracking-seq reveals the heterogeneity of off-target effects in CRISPR-Cas9-mediated genome editing

Ming Zhu et al. Nat Biotechnol. 2025 May.

Abstract

The continued development of novel genome editors calls for a universal method to analyze their off-target effects. Here we describe a versatile method, called Tracking-seq, for in situ identification of off-target effects that is broadly applicable to common genome-editing tools, including Cas9, base editors and prime editors. Through tracking replication protein A (RPA)-bound single-stranded DNA followed by strand-specific library construction, Tracking-seq requires a low cell input and is suitable for in vitro, ex vivo and in vivo genome editing, providing a sensitive and practical genome-wide approach for off-target detection in various scenarios. We show, using the same guide RNA, that Tracking-seq detects heterogeneity in off-target effects between different editor modalities and between different cell types, underscoring the necessity of direct measurement in the original system.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Tsinghua University has submitted a patent application (PCT/CN2023/071055) on the method for off-target detection used in this study, with M.Z., Y.L. and X. Lan as inventors. The remaining authors declare no competing interests.

References

    1. Doudna, J. A. The promise and challenge of therapeutic genome editing. Nature 578, 229–236 (2020). - PubMed - PMC - DOI
    1. Raguram, A., Banskota, S. & Liu, D. R. Therapeutic in vivo delivery of gene editing agents. Cell 185, 2806–2827 (2022). - PubMed - PMC - DOI
    1. Wang, D., Zhang, F. & Gao, G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell 181, 136–150 (2020). - PubMed - PMC - DOI
    1. Kim, D., Luk, K., Wolfe, S. A. & Kim, J.-S. Evaluating and enhancing target specificity of gene-editing nucleases and deaminases. Annu. Rev. Biochem. 88, 191–220 (2019). - PubMed - DOI
    1. Tao, J., Bauer, D. E. & Chiarle, R. Assessing and advancing the safety of CRISPR–Cas tools: from DNA to RNA editing. Nat. Commun. 14, 212 (2023). - PubMed - PMC - DOI

MeSH terms

Substances